

ASCO ANNUAL MEETING

Meeting Dates: June 4-8, 2021

Exhibit Dates: May 14-July 6, 2021

Submit Via Email



AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Section 1: Contact Information

Company Name.....
 Contact..... Title.....
 Tel..... Mobile.....
 Email..... Website.....
 Address.....
 City..... State..... Zip..... Country.....

I would like to receive communication from ASCO and SPARGO, Inc. regarding exhibiting opportunities at current and future ASCO meetings. To opt out of receiving these messages at any time, contact compliance.expo@spargoinc.com.

Section 2: Pharmaceutical Pipelines Directory Opportunities

(Phase listing Compound Name must be completed on the following page)

View Directory Details

<input type="checkbox"/> Early Phase 1 – \$5,000 Per Listing	# of Early Phase 1 Listings: _____	
<input type="checkbox"/> Phase 1 – \$5,000 Per Listing	# of Phase 1 Listings: _____	Total # of Listings: _____
<input type="checkbox"/> Phase 2 – \$7,500 Per Listing	# of Phase 2 Listings: _____	Total Discount/Fee*: \$ _____
<input type="checkbox"/> Phase 3 – \$10,000 Per Listing	# of Phase 3 Listings: _____	Total Cost: \$ _____
<input type="checkbox"/> Beyond Phase 3 – \$10,000 Per Listing	# of Beyond Phase 3 Listings: _____	

*Purchase three or more and get a 20% discount on all listings. Non-exhibiting companies may participate for a 20% premium fee above listing price.

The contact person provided above will receive all correspondence pertinent to the Directory, including the confirmation and fulfillment email, and will be responsible for completing and returning items by the stated deadlines. The deadline to submit your listing details is Friday, April 30, 2021. All content is subject to ASCO approval. ASCO reserves the right to make changes to content, as needed. It is the responsibility of the exhibiting company contact to ensure the company's information is submitted accurately.

Section 3: Payment Information

100% payment is due with this application. **Failure to make payments does not release the contracted or financial obligation of Company.**

Credit Card Payment

An invoice will be sent within one business day with instructions on how to submit a credit card payment online. Credit cards will also be accepted by phone at 703-631-6200 or 800-564-4220.

Submit application to:
exhibitcontracts@spargoinc.com

Check Payment

Make checks payable to: ASCO

Mail check with copy of application to:
 ASCO Exhibits Management., c/o SPARGO, Inc.
 11208 Waples Mill Road, Suite 112, Fairfax, VA 22030

Need Help? Contact:
ascoexhibits@spargoinc.com
 703-631-6200 | 800-564-4220

Section 4: Cancellation Penalties

No refund if Company cancels. Full refund if meeting is canceled by ASCO without cause.

Section 5: Acknowledgement

I acknowledge that as an authorized representative of the above stated Company, I have received, reviewed, and agree that Company will comply with the [Policies for Exhibitors and Other Organizations at ASCO Meetings](#) available on asco.org/exhibits and that Company will comply with all updates of such policies applicable to the 2021 ASCO Annual Meeting, which are subject to change at any time. Company agrees to receive all written and electronic correspondence from ASCO, SPARGO, Inc., and official event contractors in reference to the 2021 and 2022 ASCO Annual Meetings. This Pharmaceutical Pipelines Directory application will become a contract upon Company's authorized signature and ASCO's acceptance and approval.

Company Signature..... Date.....
 Printed Name..... Telephone.....

Section 6: Phase Listing Compound Name (Drug Name) (attach additional pages as needed)

Early Phase 1 Listing - Compound Name (Drug Name): _____

Early Phase 1 Listing - Compound Name (Drug Name): _____

Early Phase 1 Listing - Compound Name (Drug Name): _____

Early Phase 1 Listing - Compound Name (Drug Name): _____

Early Phase 1 Listing - Compound Name (Drug Name): _____

Early Phase 1 Listing - Compound Name (Drug Name): _____

Phase 1 Listing - Compound Name (Drug Name): _____

Phase 1 Listing - Compound Name (Drug Name): _____

Phase 1 Listing - Compound Name (Drug Name): _____

Phase 1 Listing - Compound Name (Drug Name): _____

Phase 1 Listing - Compound Name (Drug Name): _____

Phase 1 Listing - Compound Name (Drug Name): _____

Phase 2 Listing - Compound Name (Drug Name): _____

Phase 2 Listing - Compound Name (Drug Name): _____

Phase 2 Listing - Compound Name (Drug Name): _____

Phase 2 Listing - Compound Name (Drug Name): _____

Phase 2 Listing - Compound Name (Drug Name): _____

Phase 2 Listing - Compound Name (Drug Name): _____

Phase 3 Listing - Compound Name (Drug Name): _____

Phase 3 Listing - Compound Name (Drug Name): _____

Phase 3 Listing - Compound Name (Drug Name): _____

Phase 3 Listing - Compound Name (Drug Name): _____

Phase 3 Listing - Compound Name (Drug Name): _____

Phase 3 Listing - Compound Name (Drug Name): _____

Beyond Phase 3 Listing - Compound Name (Drug Name): _____

Beyond Phase 3 Listing - Compound Name (Drug Name): _____

Beyond Phase 3 Listing - Compound Name (Drug Name): _____

Beyond Phase 3 Listing - Compound Name (Drug Name): _____

Beyond Phase 3 Listing - Compound Name (Drug Name): _____

Beyond Phase 3 Listing - Compound Name (Drug Name): _____